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INVESTIGATION OF CLASS I and II ANTI-HUMAN LEUKOCYTE 
ANTIGEN ANTIBODIES IN SYSTEMIC LUPUS ERYTHEMATOSUS AND 
SCLERODERMA PATIENTS 
 
SUMMARY 
 
Human leukocyte antigen (HLA) is the human form of Major Histocompatibility 
Complex (MHC). Generally, HLA is a system of gene locus that encode for proteins 
on the surface of cells that are responsible for the regulation of the immune system. It 
is located on chromosome 6, encoded cell surface antigen presenting proteins. Anti-
HLA antibodies are normally not occurring produced against self or non-self HLA 
antigens to form a immunologic response in blood transfusion, pregnancy and organ 
or tissue transplantation.  
Systemic lupus erythematosus (SLE) is an autoimmunity disorder which 
inflammation along with tissue damage affecting multi organs such as skin, kidney, 
joint are the main cause of it. SLE is a multisystem autoimmune disorder that has 
variable clinic manifestation. Prior physiologic mechanism of SLE is polyclonal B 
cell activation and production of autoantibodies against nucleus, cytoplasmic and cell 
surface antigens. Although the main cause of SLE pathogenesis remains unclear, 
there have been several clinical and serological factors that define predisposition and 
risk for SLE. Systemic Sclerosis (SSc) that is characterized with vascular damage 
caused by immune system dysfunctions and collagen accumulation in several tissues 
and organs can cause smooth muscle atrophy result of neurological function loss and 
then motor function loss.  
Generally anti-HLA antibodies can cause acute and chronic rejection in 
transplantation. Lately, there have some studies that associated between 
autoimmunity and anti-HLA antibodies. According to new theory, it has been 
indicated that there may be a similarity between alloimmune responses occur during 
transplantation and autoimmunity for self-antigen. Microchimerism is a well-known 
phenomenon effecting after solid transplantation, pregnancy and blood transfusion. 
The analogy between autoimmune diseases and alloimmune response in 
transplantation may explain role of microchimerism related with fetal or maternal 
origin. 
Therefore, in our project, SLE and SSc were selected as a model autoimmune disease 
to investigate the relationship between autoimmunity and anti-HLA antibodies. First 
of all, three different group including SLE, SSc patients and healthy controls were 
formed. The clinical and demographic data were collected and analyzed. Then, anti-
HLA antibodies screening were done to all groups with flourometric methods. After 
analysis of anti-HLA antibodies screening, statistical analysis were done. Also, anti-
xviii 
 
HLA antibody identification analysis has been applied to anti-HLA antibody positive 
SLE, SSc patients and healthy controls. PRA ratios and CREG groups were 
determined statistically. 
According to our findings, the frequencies of both class I and II anti-HLA antibodies 
were increased in both SLE and SSc patients when compared to controls. Also, anti-
HLA antibodies frequencies were similar in both SLE and SSc patients. We also 
found that typical parameters for SLE patients such as photosensitivity, 
thrombocytopenia, anti-RNP positivity, anti-Ro positivity, anti-nuclear antibody 
(ANA) had slightly higher frequency than SSc patients. On the other hand, SSc 
parameters frequency such as digital ulcers, anti-centromere antibody, pulmonary 
hypertension, and pulmonary fibrosis were higher in SSc patients. Also, in 
comparison of degree of positivity of anti-HLA antibodies we found that patients 
with high positivity for anti-HLA antibodies in both SLE and SSc group was found 
higher than low positivity individuals in same groups. 
In conclusion, anti-HLA class I and II antibodies were found as a significantly 
increased in patients of SLE and SSc that were chosen as model autoimmune 
diseases than healthy controls in which microchimerism may play a role. In order to 
focus the role of microchimerism in this relationship, more targeted studies should be 
done. 
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SİSTEMİK LUPUS ERİTEMATOZUS ve SKLERODERMA 
HASTALARINDA ANTİ-İNSAN LÖKOSİT ANTİJEN ANTİKORLARININ 
İNCELENMESİ 
ÖZET 
İnsan Lökosit Antijenleri (HLA), majör histokompabilite komplekslerinin insan 
formlarıdır. Genel olarak, HLA bir gen lokus sistem bütünü olup, immün sistem 
regülasyonunda görevli hücre yüzey proteinlerinin kodlanmasında görev alır. 6. 
Kromozomda bulunan HLA, hücre yüzey antijen sunucu proteinleri kodlamaktadır. 
Anti-HLA antikorları ise, normal olarak oluşmayıp, kan nakli, hamilelik, doku ya da 
organ nakillerinde kendi ya da kendi olmayan HLA antijenlerine karşı üretilen 
antikorlardır.  
Sistemik lupus eritematozus (SLE), Sistemik Lupus Eritromatozus (SLE) otoimmün 
bir rahatsızlık olup başta cilt, eklem ve böbrek olmak üzere birçok organ ve dokuyu 
etkileyen iltihaplanmalara sebep olur. Multisistem bozukluğu olan SLE, değişken bir 
klinik tablo göstermektedir. SLE’nin öncelikli fizyolojik mekanizması poliklonal B-
hücre aktivasyonu ve çekirdek, sitoplazmik ile hücre yüzey antijenlerine karşı 
üretilen otoantikor üzerinden gerçekleşmektedir. Patogenezinin anlaşılması için 
birçok araştırma yapılmasına rağmen, hala tam olarak aydınlatılmamıştır. Buna 
karşılık, SLE yatkınlığına etki eden ve hastalığın kliniksel ve serolojik 
karekteristiğini belirleyen birçok risk faktörü bulunmaktadır. İmmün sistem 
bozukluklarına bağlı olarak vasküler hasarlanma ile çeşitli doku ve organlarda 
kollajen birikimi ile karakterize edilen Sistemik Skleroz (SSc), nörolojik fonksiyon 
kaybı sonucu düz kas atrofisine, ilerleyen zamanlarda da motor fonksiyon kaybına 
neden olur.  
Anti-HLA antikorları genel olarak organ nakillerinde akut ve kronik ret olgusuna 
neden olmaktadır. Son zamanlarda otoimmünite ile anti-HLA antikorları arasındaki 
ilişki üzerine yeni yeni çalışmalar yapılmaktadır. Yeni bir teoriye göre, 
transplantasyon sonrası süreçte gerçekleşen alloimmün cevap ile öz antijene yönelik 
gerçekleşen otoimmünite arasında benzerlik bulunmaktadır. Mikrokimerizm iyi 
bilinen bir olgu olup, organ nakillerinde, kan nakillerinde ve hamilelikte etkili 
olmaktadır. Otoimmün hastalıklarla, transplantasyondaki alloimmün cevabın 
arasındaki ilişkinin açıklanmasında, mikrokimerizmin rolü olduğu düşünülmektedir.  
Bu nedenle, çalışmamızda otoimmün rahatsızlıklarla, anti-HLA antikoru arasındaki 
ilişkinin açıklanması için, SLE ve SSc hastalıkları model otoimmün hastalık olarak 
seçilmiştir. İlk olarak, SLE ve SSc hastaları ile sağlıklı kontrol grupları 
oluşturulmuştur. Bireylerin klinik ve demografik verileri toplanmış ve analiz 
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edilmiştir. Daha sonra, anti-HLA antikoru taraması flourometrik yöntemle yapıldı. 
Anti-HLA antikoru tarama sonuçlarının analizinin ardından istatistiksel analiz 
yapıldı. Bu aşamadan sonra, anti-HLA antikor tarama sonuçları pozitif olan SLE, 
SSc hasta ile sağlıklı kontrollere, anti-HLA antikor tanımlama yöntemi uygulandı. 
Bu yöntem için, tarama yönteminde olduğu gibi flurometrik yöntem olan 
Luminex/xMAP yöntemi kullanıldı. Olguların PRA oranları elde edildikten sonra, 
istatistiksel analiz yapıldı. Ayrıca, olguların belirlenen CREG epitop gruplarına göre, 
reaktif anti-HLA antikorları sınıflandırılarak, bütün olgular arasında en sık rastlanan 
CREG grupları belirlendi. 
Çalışmamızdaki bulgularımıza göre, anti-HLA sınıf I ve II antikorları frekansı hem 
SLE hem de SSc hastaları gruplarında sağlıklı kontrollere göre yüksek olarak 
bulundu. SLE ve SSc hastaları grupları arasında anti-HLA antikoru karşılaştırılması 
sonucunda, önemli bir farka rastlanmadı. Ayrıca, SLE hastalığı için tipik 
parametrelerden olan, fotoduyarlılık, trombositopeni, anti-RNP antikoru pozitifliği, 
anti-RO ve anti-çekirdek antikoru pozitifliği frekansları SSc hastalarından daha fazla 
olarak bulunmuştur. Diğer yandan, SSc parametrelerinden olan parmak ülseri, anti-
sentromer antikoru, pulmoner tansiyon ve pulmoner fibroz frekansları da SSc 
hastalarında daha yüksek olarak belirlenmiştir. Ayrıca, anti-HLA antikoru pozitiflik 
derecelerine göre karşılaştırılma yapıldığında, hem SLE hem de SSc hasta 
gruplarında yüksek pozitiflik frekansı sağlıklı kontrollere göre daha yüksek olarak 
bulunmuştur. Tanımlama sonuçlarında ise, sınıf-I anti-HLA antikor PRA oranlarının 
ortalaması SLE hastalarında, SSc hastalarında daha yüksek bulunurken, sınıf-II’de 
herhangi bir farklılık görülmemiştir. CREG epitop gruplarının sınıflandırmasında ise, 
anti-HLA antikor pozitif olarak bulunan SLE, SSc hastaları ile sağlıklı kontroller 
arasında en sık rastlanan CREG grupları B4 ve B6 olarak bulunmuştur. 
Sonuç olarak, anti-HLA sınıf I ve II antikorları frekansı, otoimmün hastalık 
modelleri olarak seçilen SLE ve SSc hastalarında sağlıklı kontrollere göre daha 
yüksek bulunmuştur. Bu nedenle, mikrokimerizm rolü hakkında, bu rolün daha iyi 
belirlenmesi için daha hedefli çalışmaların yapılması düşünülmektedir. 
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1. INTRODUCTION 
1.1 Major Histocompatibility Complex 
Major histocompatibility complex is placed on chromosome 6 in humans, spanning 
over 4 centimorgans of DNA, approximately 4 x 10 
6
 base pairs. Over 200 genes are 
incorporated in humans. Genes of α chain of MHC class I molecules and β chains of 
MHC class II are encoded in the same gene region complex, whereas the genes for 
β2-microglobulin and the invariant chain are on different chromosomes (Figure 1.1). 
In humans, these genes are named as Human Leukocyte Antigen or HLA genes, and 
in mouse they are known as H-2 genes (Janeway et al., 2001). 
 
Figure 1.1 Genetic organization of the major histocompatibility complex (MHC) in 
human and mouse (Adapted from Janeway et al., 2001) 
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Although the organization of genes can be varied differently, MHC genes are divided 
into regions encoded three types of molecules. Glycoproteins that are expressed on 
the surface of most of nucleated cells are encoded by class I MHC genes. The major 
role of product of these genes is antigen presentation to Tc cells. Class II MHC genes 
encode glycoproteins expressed mainly on antigen presenting cells (macrophages, B 
cells and dendritic cells) and those antigen presenting cells present processed 
antigenic peptides to Th cells. Class III MHC genes are involved encoding some 
secreted proteins which have major immune functions such as components of 
complement system and inflammation molecules (Kindt et al., 2007). 
As a general view, peptide (or antigen) presentation to T-cell receptors is the main 
function of MHC class I and II (Danchin et al.,2004)  More specifically, general 
function of  MHC molecules is to interact with peptide fragments from pathogens 
and present them on the cell surface in order to recognize by the appropriate T cells. 
The results of this process are always destructive to the pathogen and are concluded 
with macrophage activation to kill bacteria living in their intracellular vesicles and B 
cell activation to produce antibodies for elimination and neutralization of 
extracellular pathogens (Janeway et al., 2001). 
1.1.1 Human Leukocyte Antigen 
Human leukocyte antigen (HLA), is the human form of MHC with same function, 
are divided into 3 same groups as in MHC, Class I, II and III. HLA Class I genes 
contain 2 group of genes; one group is classical which consists of HLA-A, HLA-B 
and HLA-C and the non-classical group contains HLA E, HLA-F and HLA-G. Class 
II subregion also contain 3 separate group such as HLA-DR, HLA-DP and HLA-DQ. 
Class III region exclusively encodes some important immune response products like 
TNF genes, LTA and LTB genes (Mehraet al.2010). 
Basically, HLA molecules were defined with serological methods by utilizing 
antibodies specific for variable HLA class I and II molecules. With that reaching, a 
terminology for nomenclature and definition of HLA antigens was established. For 
instance, HLA-A2 is different from HLA-A25, HLA-B18 from HLA B-27 etc. The 
development of PCR technologies leads to more informative about differences 
between HLA molecules. For example, present terminology indicate HLA-
DRB1*1301, in which the letters to the left of asterisk define the HLA gene, and the 
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four digit to the right of asterisk point out the particular HLA allele. That major and 
informative nomenclature of HLA alleles has been quite useful for scientists and 
clinicians to try matching organ donors and recipients and also specify individuals 
who have been risk for autoimmunity (Coico& Sunshine, 2009). 
1.2 Humoral immune system 
1.2.1 B cells 
Most of the pathogenic bacteria divide in human in the extracellular part of the body 
and many intracellular pathogens can be transported into all cells with the help of 
extracellular fluids. Those extracellular parts of human body are protected by 
humoral immune response by secreting antibodies in B cells for destruction of 
extracellular pathogens and block the spread of the intracellular infections. 
Differentiation of B cells into antigen secreting plasma cells after activation of them 
occur via antigen trigger and generally need helper T cells. Helper T cell is Th2 class 
of CD4 cells, and a subgroup of Th1 cells can be also effective in B cell activation 
(Janeway et al., 2001). 
B lymphocytes have antibody molecules on their surface and antibodies can only 
interact with one specific antigen, especially antigenic determinant. T lymphocytes 
that are component of cell mediated immunity, express receptors specific to short 
peptide sequences related with MHC molecules present on the cell surface. 
Therefore, humoral immunity is specific to many different proteins, polysaccharides, 
lipids, toxins and lipopolysaccharides that secreted by spreading pathogens in the 
blood stream (Khan, 2009) 
B lymphocytes are fundamental component of humoral immune system and 
basically, produce antibodies during immune response (Honjo et al., 
2014).Generally, B lymphocytes are induced by antigens, and after activation they 
mainly differentiate into plasma cells. The plasma cell form of B cell is known as 
antibody-producing cells, with the help of T cell interaction. B cell receptor (BCR), 
which is comprised of surface immunoglobulin (Ig), can recognize antigen 
(Chaturvedi et al., 2012).  
1.2.2 Antibody 
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Antibody, also known as immunoglobulin (Ig), is large Y-shaped protein structure 
produced by plasma B cells (Litman et.al, 1993) General functions of antibody are to 
bind foreign and non-self-molecules, basically antigens, neutralizing them or 
induction of their removal. Antibodies can be produced at vast variability, they can 
be structurally similar (all Y-shaped molecules) but they are unique. The chemical 
features of antibodies defines three functions of antibodies; 1) binding versatility, 2) 
binding specificity and 3) biological activities. An antibody molecule consist of four 
polypeptide chains with a molecular weight about 150 kD (Figure 1.2). These four 
chains are split into two identical light chains and two heavy chains (Elgert, 2009). 
The terms of heavy and light means the relative size of the proteins. Each light chain 
is covalently bound to a heavy chain and the heavy chains are also bound each other 
covalently. Both light and heavy chains of the antibody structure are similar. Each 
component has two regions, a variable (V) and a constant (C) region. The variable 
region of the light chain comprise two definite fragment named as ‘V’ and ‘J’. 
However, the heavy chain contains three segments, named as ‘V’, ‘D’ and ‘J’. Two 
variable regions from heavy and light chain define specificity of an antibody 
molecule (Jacqueline, 2012). 
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 Figure 1.2 Antibody (Imunoglobulin) structure (adapted from Jacqueline, 
2012) 
Antigenic determinants that characterize antibody classes are called isotypic 
determinants and the classes are indicated as isotypes (Figure 1.3). The five different 
classes of immunoglobulins are defined as IgG, IgM, IgD, IgE and IgA (Elgert, 
2009).  
 
Figure 1.3 Types of immunoglobulins (adapted from Berg et al., 2007) 
1.2.2.1 Immunoglobulin E 
Immunoglobulin E (IgE) antibodies are notably crucial in effective immune response 
to some parasites, especially in helminth infections in gastrointestinal tract. The Ig-E 
antibodies can interact to cells with FcεR receptors such as eosinophils, mast cells 
and basophils. The eosinophils secrete cytotoxic protein, after parasite/Ig-E complex 
binding to FcεR on eosinophils. Moreover, histamine released by mast cell and 
basophils since IgE make a crosslink with helminthes (Jacqueline, 2012).  
1.2.2.2. Immunoglobulin D 
Membrane form of immunoglobulin D (IgD) is primarily crucial since the soluble 
form is found in bloodstream and other body fluids moderately low. IgDtend to be 
capable of transducing activating and tolerizing signals, when it is found along with 
Ig-M on all mature, naïve B cells (Chaturvedi et al., 2012). 
1.2.2.3. Immunoglobulin A 
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Immunoglobulin A (IgA) is produced in most amount among all antibody isotypes. 
The main function of IgA is to manage homeostasis at mucosal surface and immune 
response. Also, Ig-G plays an important role in avoiding tissue damage in several 
multiple autoimmune and inflammatory diseases (Mkaddem et al.,2014) 
1.2.2.4 Immunoglobulin M 
Immunoglobulin M (IgM) is an antibody isotypes that has the highest molecular 
weight among all other isotypes. There are two types of IgM structurally; monomeric 
and pentameric. Monomeric IgM is used as an antigenic receptor by the B cells and 
is produced as membrane bound antibody on B cells. Pentamer IgM is produced by 
permablast cells. In spite of abundance of IgA in secretory fluids, IgM has an 
important function as a secretory immunoglobulin. Also, IgM is the first 
immunoglobulin that is secreted by the neonates (Rao, 2002). Moreover, IgM has 
more valency than other antibody isotypes since it has pentameric structure with the 
help of 10 antigen binding sites. However, IgM cannot diffuse easily due to its large 
molecular size, so the amount of IgM is very low at intercellular tissue fluids (Kindt 
et al., 2007) 
1.2.2.5 Immunoglobulin G 
Immunoglobulin G (IgG) is the important class of immunoglobulins in serum. IgG 
can be found in extravascular spaces, not only the bloodstream. Also, IgG can be 
transported into the placenta so passive immunity in the fetus and neonates can be 
established. IgG is responsible for important function such as complement fixation, 
precipitation, neutralization of toxins and viruses (Mohanty&Leela, 2013). IgG can 
be investigated under four different subclasses according to their decreasing amount 
respectively, IgG1, IgG2, IgG3, and IgG4. Also, IgG antibody can give a response to 
an antigen related to their subclasses. Selective subclass deficiencies are not 
generally harmful to individuals but in some specific conditions do cause to 
increased susceptibility of some specific class of pathogens. That harmful effect can 
be caused whole isotype or subclass deficiency because of some deletions of Ig loci 
(Vidarsson et al., 2014)  
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1.3 Anti-HLA Antibodies 
Anti-HLA antibodies or antibodies against human leukocyte antigens are antibodies 
that produced specific to HLA and play a major role in graft survival, especially solid 
organ transplantation (Maccarone et al., 2005) Exposure of HLA antigens in blood 
transfusion, pregnancy or transplantation can lead the formation of antibodies 
specific for HLA antigens. This phenomenon called as a sensitization. The presence 
of those anti-HLA antibodies is harmful in especially organ transplantation when 
HLA antigens of donor match with the recipient’s antibody. The quantity of HLA 
antibodies can be detected with testing serum from individuals in order to presence 
of HLA antibodies. In this measurement, an estimate of the amount of sensitization is 
measured with calculation of panel reactive antibodies (PRA) that is the number of 
cells that interacts positively with the serum divided by the number of cells in the test 
panel, times 100, equals the percent PRA. The percent PRA most likely determine 
what percentage antibodies of patients react with donor HLA (Adelman et al, 2002). 
In transplantation process, recipient blood vessels are anastomosed to the vessels 
belong to the donor on the donor graft; recipient blood goes through the graft and is 
reacted with endothelial cell lining the donor vessels. Any preformed HLA 
antibodies in the recipient can attack the cells by fixation of complement and 
activation of complement system since endothelial cells can express both class I and 
II antigens. This phenomenon is named as hyperacute rejection and can be avoided 
with the development of more sensitive antibody detection method (Mehra et al, 
2010). 
There are two phases of evaluating HLA antibodies presence; screening and 
identification or detection of specificity. Screening of evaluating presence of anti-
HLA antibodies (also named as lymphocytotoxic antibodies) is the first medical 
procedure after immunizing cases such as transfusion, transplant rejection, pregnancy 
and any change during immunosuppression therapy. Identification or detection of 
anti-HLA antibody specificity is performed for the determination of the HLA 
phenotypes of the test cells which the antibody is reactive. For instances, if all of the 
test cells that reacted positively with the serum have HLA-A1 in their HLA 
phenotypes, the antibody specificity of the patient is considered to be anti-A1. Some 
antibodies can be reactive with epitopes which is common among several HLA 
8 
 
antigens. These antigen groups are named as CREGs (cross-reactive groups). 
Identifications of the antibody specificities of patients for transplantation candidates 
are remarkable factor for the selection of suitable organ donor. Transplantation of an 
organ to the previously sensitized with an HLA antigen is undesirable practice in 
organ transplantation procedure (Adelman et al., 2002). There are two distinct anti-
HLA antibody screening methods that have been commonly used for HLA antibody 
screening such as Cell based (cytotoxic), solid phase anti-HLA antibody screening 
methods. 
1.3.1 Cell based (cytotoxic) anti-HLA antibody screening methods 
For several years, the basic and common technique in HLA antibody screening was 
complement dependent cytotoxicity (CDC) assay. The CDC technique based on 
living T cells for class I antibody identification and living B cells for class I and II 
antibody identification. The CDC technique is relatively time-consuming, 
inconvenient and also requires testing a few panel donors to contain all major 
features or depending on commercially available frozen cell trays or immortalized 
lymphoblastic cell lines (LCLs). In these tests, only complement fixing antibodies 
can be detected. In spite of CDC assays being time-consuming and inconvenient, 
they have advantage of easy determination of antibodies of IgG and IgM isotype with 
adding dithiothreitol (DTT) (Howell et al., 2010).  
Cell donors are chosen in a population by chance in order to contain variable HLA 
types and their lymphocytes from panels of cells. The HLA typings of these cell 
donors are the representative of the general distribution in same population from 
cadaveric donor (Figure 1.4). Only difference between serologic typing and the basic 
method of cell based HLA antibody screening is mixing cell donor lymphocytes and 
recipient serum in all wells along with complement and vital dye (Chandraker et al., 
2012). 
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Figure 1.4 Schematic demonstration of cell-based HLA antibody screening method 
(adapted from Tinckam, 2009) 
1.3.2 Solid phase anti-HLA antibody screening methods 
It has been reported that antibody-mediated damage can occur without any detectable 
antibody with the usage of cell based (cytotoxic) antibody screening method. For this 
reason, more sensitive assays have been developed. In order to analyze HLA 
antibody and non-HLA antibody separately as well as class I and II, developed solid 
phase methods have been created. Instead of usage of lymphocyte targets with both 
HLA and non-HLA antibody, solid based screening methods use soluble or 
recombinant HLA molecules (Figure 1.5). In those techniques, after purified 
molecules bind on ELISA platforms or beads, they interact with only HLA antibody 
in the added recipient serum (Tinckam, 2009). Generally, there are two different 
solid based anti-HLA antibody screening methods such as ELISA and flow 
cytometry/X-map techniques. 
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Figure 1.5 General schematic of solid phase HLA screening method (adapted from 
Chandraker et al., 2012) 
1.3.2.1 Anti-HLA antibody screening with ELISA 
In ELISA (enzyme-linked immunosorbent assay) method for HLA antibody 
screening, multiwall plates which have purified HLA antigens bound to individual 
wells. After sample serum is added and washed to eliminate unbound unwanted 
antibody, reactive HLA antibody can be detected using labelled anti-human 
antibodies (Torpey et al., 2010)  
ELISA PRA assays utilize soluble HLA antigens bound onto wells of an ELISA 
plate. Test sera are added to the individual wells, antibodies can bind to the related 
antigens when the sera contains HLA antibody. Antibody-antigen complexes can be 
detected with horseradish peroxidase-conjugated anti-human IgG antibody. With the 
enzyme-substrate interaction, substrate can be catalyzed into a colored product which 
provides measurement of light with absorbance ratio. The measurement is made with 
ELISA plate reader and analyzed with software in computer (Rudmann, 2005).  
1.3.2.2 Anti-HLA antibody screening with flow cytometry/xMAP (Luminex) 
techniques  
Flow cytometry/xMAP (Luminex) techniques depend on soluble and recombined 
HLA molecules on polystyrene particles and these assays are the gold standard for 
both antibody screening and identification. The xMAP (Luminex) assay has two 
distinct recording systems. First system is a laser that measure changes in 100 
individual polystyrene particles. Those particles are colored with numerous amounts 
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of two different fluorochromes that make particles unique. HLA antigens or a single 
antigen interact with each bead set. For antibody binding, test serum is added on to 
beads. Second anti-human antibody with a reporter molecule is also added into the 
reaction mix, fluorescence from reporter molecule is measured by the laser. 
Therefore, semi-quantitative antibody level in the test serum is determined (Howell 
et al., 2010). 
HLA antibody screening and identification with flow cytometry depends on 
availability of tools in laboratory. In flow PRA method, there are two different 
techniques. First technique is a house method in which whole lymphocytes are used 
as an antigen and second technique is commercial kits which contain beads with 
coated and recombined HLA antigens. Commercial flow PRA kits are demonstrated 
to be more sensitive than cell-based HLA antibody screening method (Hajeer, 2006). 
1.4 Autoimmunity 
An autoimmune response or autoimmunity can be defined as an attack of the immune 
system to the host itself. For all healthy individuals, immune system is tolerant to self 
but reactive foreign molecules defined as non-self such as bacteria and viruses. The 
ability of immune system in separating self from non-self is thought to be the crucial 
factor in immune system response. Autoimmunity phenomenon defines a precise 
damage to the mechanism which immune system regulates their activation. 
Interestingly, the effector mechanism of autoimmunity is not so different from 
normal immune response; they use same molecules such as antibodies and as well as 
cell-mediated immunity components. There is no single mechanism that has been 
determined for the diversity of autoimmune responses or the autoantibodies 
production (Figure 1.6) (Pollard, 2006). 
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Figure 1.6 Hypothetical pathway of autoantibody formation in autoimmunity 
(adapted from Pollard, 2006) 
Since decades, the pathogenesis of the autoimmune diseases has been defined as a 
group of disorders with involvement of multi-organ or single-organ system. 
Highlight of these clinical features is enhanced activity of immune system against 
self with abnormalities in immune system components. The immune system 
normally defend the body against non-self-pathogens by using T and B lymphocytes 
as a tool, that direct antigen receptors and innate immune cells activated with a signal 
from pathogen and damaged molecules. This defense against pathogens must occur 
without leading any harm to self. For this reason, self-reactive T and B cells are 
discriminated in the thymus and bone marrow with the process called ‘negative 
selection’. Negative selection process however can be defected and self-reactive 
lymphocytes can go through the periphery but tolerance mechanism must keep these 
cells under control. If regulatory and effector component of immune system are 
broken, self-reactive T and B cells can activate and cause autoimmunity (Smilek and 
Clair, 2015). 
1.4.1 Autoimmune diseases 
In civilized countries, autoimmune diseases are the major cause of death and 
morbidity and this situation leads to spend lot of money for health care. The 
pathogenesis and key factors of autoimmunity have not been known strictly. In order 
to enlighten these factors, important questions such as origin of autoantibodies, and 
their association with autoantigens must be solved (Gershwin and Shoenfeld, 2000).  
When autoimmune diseases are classified, there are two branches of autoimmune 
disorders with immunity against self-antigens and without detectable anti-self 
response. Rheumatoid arthritis (RA), systemic lupus erythematosus, multiple 
sclerosis, type-1 diabetes, and celiac disease belong to the autoimmune diseases 
group of relation with autoantibody production and rarely reactive T cells. Other 
group includes psoriasis, inflammatory bowel disease, or ankylosing spondylitis; 
adaptive immune system is effective their pathogenesis (Smilek and Clair, 2015). 
The etiology of many autoimmune disorders is unknown. On the other hand, 
microbial infection can be the trigger or initiation factor for autoimmunity induction. 
13 
 
There are several mechanisms to clarify this relation, including molecular mimicry, 
bystander activation and tissue damage leading to initiation of autoimmunity. In 
molecular mimicry, a microbial antigen or epitope mimics a self-antigen/epitope 
which T cells can be re-stimulated with endogenous self-antigens following 
microbial infection and so T cells can target cells or tissues expressing self antigens 
resulting in tissue damage. Bystander activation process can be occurred via random 
induction of potentially self-reactive T cells causing tissue damage. Tissue damage 
leading to initiation of autoimmunity mechanism is the result of microbial infection 
via the release of endogenous self-antigens that can be presented by APCs (antigen 
presenting cells) resulting in activation of self-reactive T cells (Shoenfeld et al., 
2015) 
1.4.2 Systemic Lupus Erythematosus 
Systemic lupus erythematosus (SLE) is an autoimmune disease that can cause 
inflammation affecting multiple tissues and organs including skin, joint and kidney 
(Sherer et al., 2004). Variable clinical features of SLE are correlated with the 
complexity of genetic, hormonal and environment factors and diversity of 
autoantibodies (Lisnevskaia et al., 2014). Primary physiological mechanisms of SLE 
are polyclonal B-cell activation and autoantibody production against cytoplasmic, 
cell surface and nuclear antigens (Marchini et al., 2013)  
Measurement of SLE disease activity is the problem for scientists and physicians for 
treating patients. Nowadays, there have been some valid and sensitive indices such as 
BILAG (British Isles Lupus Assessment Group), ECLAM (European Consensus 
Lupus Activity Measurement), SLAM (Systemic Lupus Activity Measure), SLEDAI 
(Systemic Lupus Erythematosus Disease Activity Index), and LAI (Lupus Activity 
Index). Until antinuclear antibody (ANA) was introduced, there is no valid test for 
diagnosis. Common clinical symptoms are malaise, over-whelming fatigue, fever and 
weight loss. Even, there are some similarities in some organ manifestations including 
skin diseases and arthritis, other systems or organs can be present together with other 
features (Tsokos et al., 2007).  
It is a common fact that a number of environmental molecules or factors of SLE can 
corrupt autoreactivity by changing epigenetic mechanism. Generally, epigenetic 
mechanisms are DNA methylation and histone modifications which include 
14 
 
methylation of cytosine base of the DNA and deacetylation, ubiquination and 
trimethylation of histone tails, in order. Those epigenetic mechanisms can block gene 
transcriptions with numerous silencing of the expression of certain unnecessary and 
harmful genes. Beside epigenetics, there are numerous environmental factor that can 
create conditions that lead patients to SLE such as ultraviolet light, Vitamin-D 
deficiency, smoking, alcohol, occupationally and non-occupationally-related 
chemicals (Mak and Tay, 2014).  
Although hormonal, environmental, genetic and epigenetic factors are considered to 
cause SLE, pathogenesis of this disorder needs to be clarified a little more. Normally, 
mature B cells produce antibodies to protect cells against exogenous pathogens. 
Auto-reactive B and T cells are generally eliminated from circulatory system during 
a negative selection step in their maturation phase. SLE is thought as a B cell disease 
because many lupus patients have high ratio of reactive autoantibodies against 
nuclear antigens related to their targets and to complement factors, which form 
circulating immune complexes (CICs).  CIC accumulation in target organs and 
tissues induce and trigger an inflammatory process resulting in symptoms of SLE. 
SLE activity is correlated with ratio of autoantibodies, especially IgG and anti-
dsDNA. Production of these autoantibodies in high level in SLE patients is the result 
of many abnormal immunological events in both adaptive and innate immune system 
components. Genetic and environmental factors could affect the loss of tolerance of 
T and B cells (Dema, 2014). 
1.4.3 Systemic Scleroderma 
Systemic Scleroderma (Sclerosis-SSc) is a chronic autoimmune disorder effecting 
multiple systems and organs, characterized with microangiopathy and fibrosis of the 
internal organs and skin. There are two important subtypes of SSc such as SSc with 
limited cutaneous involvement and SSc with diffuse cutaneous involvement 
(Lambova, 2014).  
Scleroderma is an autoimmune and also a vascular disease with injury of blood 
vessels resulting in abnormal blood vessel function and fibrotic or scarring disorder 
involving multiple systems. Therefore, thickness and hardness increase with 
accumulation of collagen and several proteins in skin, also lungs, heart and 
gastrointestinal tract. The correlation of vascular assets of SSc and fibrotic assets of 
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SSc with autoimmune and inflammatory events make the treatment and 
understanding of pathogenesis difficult (Thompson and Ensz, 2003). 
SSc can be also characterized with Raynaud’s phenomenon and other vascular 
abnormalities, immune system activation seen by SSc-specific autoantibodies, in 
particular anti-centromere proteins (CENP), anti-topoisomerase I (topo I, also called 
Scl-70) and anti-RNA polymerase III (RNAP) and disorder in fibroblast function 
leading skin thickness and fibrosis. SSc is quite life effecting disease seen in 
especially women with age of around 45, causing social disability, high cost and 
increased mortality with lung disease and pulmonary arterial hypertension (Hudson 
and Fritzler, 2014) 
1.4.4 Major Clinical Parameters and Autoantibodies for Systemic Scleroderma 
and Systemic Lupus Erythematosus 
1.4.4.1 Pleuritis 
Pleuritis also known as pleurisy defines pleura inflammation with surroundings of 
lungs. Many factors can play role in pleuritis but viral infection that spreads from the 
lungs to plural cavity is most common. Inflamed pleural layers touch each other in 
breathe process so pleuritic chest pain can occur. Also, in systemic lupus 
erythematosus pleuritis is one of symptoms (Husain, 2012) 
1.4.4.2 Pericarditis 
Pericarditis is the inflammation of the pericardium characterized with chest pain. 
There are several factors for pericarditis but mainly autoimmune (SLE) and 
microbial infection. Based on duration and time of presentation, there are two forms 
of pericarditis; acute and chronic form (Gorbach et al., 2004).  
1.4.4.3 Nephritis 
Nephritis is the inflammation of the kidneys involved in glomeruli, tubules or 
interstitial tissue around the glomeruli and tubules. If this inflammation is caused by 
systemic lupus erythematosus, it is called as lupus nephritis (Schiffer et al., 2015). 
1.4.4.4 Pulmonary Hypertension 
16 
 
Pulmonary hypertension indicates different conditions generally occur with increases 
in pulmonary arterial pressure. Basically, pulmonary hypertension occurs with 
elevations of blood pressure exactly in pulmonary artery, pulmonary vein, or 
pulmonary capillaries and the symptoms are shortness of a breath, dizziness, fainting, 
and leg swelling (Hill and Farber, 2008). 
1.4.4.5 Antinuclear Antibody (ANA) 
Antinuclear antibody (ANA) is a type of autoantibody produced against cellular 
proteins and nuclear acids. Although the name indicates produced against ‘nuclear’ 
antigen, ANAs are partially or completely located on cell cytoplasm. The common 
produced ANAs react with DNA-protein or RNA-protein complexes. ANAs are 
produced with high titer and have high affinity IgG antibodies which are produced 
with T-cell dependent process induced by the autoantigen. Antinuclear antibody 
testing is the best indicator for diagnosis of SLE and is the most-ordered tests in 
clinics (Petrelli, 2008). 
1.4.4.6 Anti-double stranded DNA antibody (anti-dsDNA) 
Anti-double stranded DNA (anti-dsDNA )  antibody is the autoantibodies directed to 
double stranded DNA structure. Anti-dsDNA antibody can be produced in 40% to 
80% of people who have SLE. These autoantibodies provide monitoring the 
treatment of lupus besides diagnosis of SLE since anti-dsDNA level can be increase 
or decrease with the activity of disorder. Also, people with anti-dsDNA antibody 
have increased risk of having kidney lupus disorder or vasculitis with their disease 
(Thomas Jr., 2014).  
1.4.4.7 Anti-RO/SSA antibody 
Anti-RO/SSA autoantibodies are the most common anti-extractable nuclear antigens 
and are generally related with SLE and Sjögren’s syndrome. The double name of 
anti-RO/SSA autoantibodies came from that two different research groups has 
defined it simultaneously (Lahita et al., 2010). These autoantibodies are related with 
common type of human RNA in a complex as hYRNA. Anti-RO antibody positivity 
is the indicator of a number of dermatologic conditions. Also, anti-RO/SSA 
antibodies are related with hematologic abnormalities, especially thrombocytopenia 
(Lotze and Thomson, 2011).  
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1.4.4.8 Anti-ribonucleoprotein antibody (anti-RNP) 
Anti-ribonucleoprotein (anti-RNP) antibody is related to antigens in small nuclear 
ribonucleoprotein particles. Anti-RNP antibodies can be found in rheumatoid 
arthritis, Sjögren’s syndrome, systemic sclerosis (SSc) and SLE. Diagnostically, anti-
RNP antibody test is not considered as suitable for diagnosis of SLE because of low 
sensitivity and moderate specificity (Wallace and Hahn, 2012).  
1.4.4.9 Anti-Smith antibody (anti-Sm) 
Anti-Smith (anti-Sm) antibodies can react to several antigens in small 
ribonucleoprotein particles that have a role in splicing of precursor messenger RNA. 
There are variable methods for detection of anti-Sm antibodies such as 
immunodiffusion, ELISA, counterimmunoelectrophoresis and multiplex bead assays. 
Although about 30% of patients who have SLE are positive for anti-Sm antibodies, 
these autoantibodies have important diagnostic value since they can be found in other 
rheumatic disease such as scleroderma, rheumatoid arthritis (Wallace and Hahn, 
2012). 
1.4.4.10 Anti-ribosomal protein P antibody 
Anti-ribosomal protein P autoantibodies produced specifically in SLE disease. Three 
highly conserved ribosomal phosphoproteins are the molecular target of these 
autoantibodies. Indicated prevalence of anti-P antibodies among SLE patients can 
vary from 6% to 46%. In addition to association between SLE and anti-P 
autoantibody, some clinical association between hepatitis, nephritis and anti-P 
antibody have also been reported (Haddouk et al., 2009). 
1.4.4.11 Anti-centromere antibody 
This antibody is produced against centromere protein that is a tool in diagnosis of 
CREST syndrome. In spite of abundance in CREST syndrome, about 10% of 
scleroderma patients can have these autoantibodies. These antibodies are present 
early in the course of disease and are especially cutaneous involvement (Wild, 2005).  
1.4.4.12 Anti-Scl-70 antibody 
18 
 
Anti-Scl-70 (also known as anti-topoisomerase-I) antibody specifically related with 
diffuse cutaneous disease. Anti-Scl-70 positivity indicates higher prevalence of 
arthritis, tendon fraction rubs, severe pulmonary fibrosis, severe heart disease and 
SSc. Also, patients with anti-Scl-70 antibody have higher risk for microvasculature, 
digital tip ulcers, gangrene and digital tuft resorption. The target molecule for anti-
Scl-70 is topoisomerase antigen which is obtained from a 70 kD extractable 
immunoreactive fragment (Varga et al., 2012).  
1.4.4.13 Antiphospholipid syndrome 
Antiphospholipid syndrome (APS) is a common systemic autoimmune disorder 
manifested with thrombophilic situation and by obstetrical symptoms. The 
association between antiphospholipid syndrome and autoimmune disorder (especially 
in SLE) is primarily close. Up to 15% of SLE patients can have APS and also 50% of 
the patients with APS are SLE patients. The female ratio according to male is 2:1 
(World Health Organization, 2006). The presence of antiphospholipid antibodies 
(aPL) is the primer criteria for the diagnosis of APS and other two typical 
autoantibodies are the lupus anti-coagulant (LA) and anti-cardiolipin antibodies 
(aCL). aPL autoantibodies are a specific group of antibodies produced against 
phospholipid binding proteins. aCL are measured with ELISA. The LA antibodies is 
a misnomer that it might be produced in patients without lupus and it is actually 
prothrombotic autoantibody (Mason and Pusey, 2007).  
1.5 Aim of the Study 
Anti-HLA antibodies are related with acute and chronic rejection in all solid 
transplant recipients. According to newest theory, there is a significant similarity 
between alloimmune response in the post-transplant period and the development of 
autoimmunity against self-antigens. Although, the role anti-HLA antibodies in the 
pathogenesis of autoimmune disorders remain unclear, some theories have been 
suggested. One of those theories is antibody production against self-antigens that 
caused by microchimerism. However, there is few studies that have been investigated 
the role of anti-HLA antibodies in autoimmune disorders in the literature. 
In our study, anti-HLA antibodies presence was investigated in patients with SLE, 
SSc which were selected as a model autoimmune disorder, and also in healthy 
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controls. Also, demographic and clinical data of individuals were studied and tried to 
establish correlation between clinical data and anti-HLA antibody presence. Also, 
anti-HLA antibody identification experiment was maintained to find a relationship 
between specific anti-HLA antibody type and autoimmune disorder. 
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2. MATERIALS & METHODS  
2.1 Materials 
2.1.1 Patients and Controls 
We included 77 SLE and 46 SSc patients who were being treated at the Trakya 
University Medical School, Department of Rheumatology. Also, 53 healthy controls 
were included to this study. All patients and controls were signed written informed 
consent form and were given a copy of same form. The study was approved by the 
local ethics committee at Trakya University Medical Faculty and it conformed to the 
provisions of the 1995 Declaration of Helsinki (as revised in Edinburgh 2000). 
2.1.2 Commercial Kits 
All commercial kits that were used in this study are listed with their supplier 
companies in the table below. 
Table 2.1 Commercial kits used in this study. 
Commercial Kit Supplier Company 
Life Screen Deluxe Anti-HLA Class I 
and Class II Screening kit 
Lifecodes 
Life Screen Deluxe Anti-HLA Class I 
and Class II identification kit 
Lifecodes 
 
2.1.3 Equipment 
Laboratory equipments which were used in this study are shown in Table 2.2 with 
their suppliers. 
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Table 2.2 Laboratory equipment used in this study. 
Equipment Supplier Company 
Centrifuge Thermo Scientific 
Pipettes 10 µl, 20 µl, , 200 µl, 1000 µl 
Thermoand 100 µl, 1000 µl Ependorf 
Vortex Biosan 
Vacuuum Pump Millipore 
Serum Seperator tubes Beacon Diagnostics 
Fridge (-20
o
 C) Arcelik 
LuminexFluoroanalyzer Lifecodes 
UPS Imtek 
Printer Lexmark 
Filtered plate (96 wells) Millipore 
Vacuum Filter Millipore 
Eppendorf 1.5 ml tubes ATQ 
Falcons (15 ml, 50 ml) ATQ 
Pipette tips (10 µl, 20 µl, , 100 µl, 200 
µl, 1000 µl) 
ATQ 
Sterile Gloves Bend 
Minispin Centrifuge Hangzhou 
Fridge (-80
o
 C) Haier 
Sheath  Beacon Diagnostics 
 
2.1.4 Softwares 
All softwares which were used in this study for data analysis are shown in Table 2.2 
with their suppliers. 
 
 
Table 2.3 Softwares used in this study. 
Software Supplier Company 
Quicktype Match 2.6 xMAP software Lifecodes 
SPSS IBM 
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2.2 Methods 
2.2.1 Patient Selection 
In this study, we included 77 SLE and 46 SSc patients who were being treated at the 
Trakya University Medical School, Department of Rheumatology. 1997 American 
college of Rheumatology (ACR) criteria were used for the diagnosis of SLE. Patients 
who were suitable at least four criteria of 1997 American college of Rheumatology 
were counted to be diagnosed as SLE. SSc patients were also diagnosed according to 
ACR criteria. The inclusion criteria of SLE and SSc patients were being older than 
age of 30, being fulfilled according to ACR criteria and patients must be classified 
according to European Consensus Lupus Activity Measurement index. The exclusion 
criteria of SLE and SSc patients were being younger than age of 30, using anti-CD20 
therapy, receiving transplants and having a diagnosis of another autoimmune disease. 
The inclusion criteria of healthy controls were older than age of 30 and not being 
diagnosed as an autoimmunity disease.  
2.2.2 Collecting of Demographic and Clinical Data of Patients and Controls 
All demographic and clinical data of both patient and controls were kindly provided 
from Trakya University Medical Faculty hospital files by Rheumatology 
Department. Also, all patients were fully examined physically by same department. 
Laboratory data taken from Rheumatology department included whole blood counts, 
biochemical tests, antinuclear antibody (ANA), anti-double-stranded DNA (anti-
dsDNA) and extractable nuclear antigen (ENA). Moreover, SLE Disease Activity 
Index (SLEDAI) of the SLE patients was kindly requested from same department 
and it has been calculated for each SLE patient at the time of initial diagnosis. 
2.2.3 Serum Separation 
Serum separation process was started with blood taken procedure. Two milliliters of 
blood were taken from both patients and controls with sterile injector and were 
drawn into serum separator tubes. Tubes were centrifuged at 2000 x g for 10 
minutes. After centrifugation process, serum which was the upper part of three layer 
of centrifuged blood was taken with micropipette into 2 ml Eppendorf tubes. Then, 
Eppendorf tubes were labelled, numbered and stored at -20
o
 C until Anti-HLA 
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Antibody Screening studies begin. After experiment was done, sample serum was 
stored at -80
o
C permanently. 
2.2.4 Anti-HLA Antibody Screening 
Anti-HLA antibody screening studies were carried by Lifocodes anti-HLA Class I 
and Class II Screening kits (Lifecodes, Immucor, Norcorss, GA, USA). First of all, 
300 µl sterile distilled water were added into wells of Millipore filtered plates in 
order to make wells wet. After 2-5 minutes waiting period, plate was vacuumed at 
the vacuum pump briefly. At the same time, Lifescreen deluxe beads were 
centrifuged briefly at 1500 x g for 15-30 seconds and then mixed with vortex. After 
that, mix components which were given at Table 2.4 were added each wells 
respectively. 
 
Table 2.4 Screening protocol mix components. 
Component Amount 
Wash Buffer 40 µl 
Serum Sample 12,5 µl 
Class I-II Beads 5 ul 
 
Plate was sealed and incubated for 30 min at room temperature avoiding light in 
shaker. During incubation, conjugant mix was prepared for every sample with 
amount given at Table 2.5 and was stored in the dark until usage.  
Table 2.5 Conjugant mix components. 
Component Amount 
Wash Buffer 45 µl 
Conjugant 5 µl 
 
After incubation of samples, 100 µl wash buffer was added into wells, mixed and 
vacuumed at the vacuum pump briefly. Then, 300 µl wash buffer was added into 
wells, mixed and vacuumed again and this step was repeated three times. 50 µl of 
prepared conjugant mix were then added into wells. Plate was sealed incubated for 
30 min at room temperature avoiding light in shaker. At the end of the incubation, 
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150 µl wash buffer was also added into wells and mixed. Plate was loaded into 
Luminex after necessary wash, calibration was done and all samples were analyzed 
at xMAP software (Luminex Co, Hertogenbosch, The Netherlands). 
2.2.6 Anti-HLA antibody identification 
Anti-HLA antibody identification studies were carried by Lifecodes anti-HLA Class 
I and Class II Identification kits (Lifecodes, Immucor, Norcorss, GA, USA). For this 
experiment, 17 anti-HLA positive SSc patients, 37 anti-HLA positive SLE patients 
and 4 anti-HLA positive healthy controls were included. First of all, 300 µl sterile 
distilled water was added into wells of Millipore filtered plates in order to make 
wells wet. After 2-5 minutes waiting period, plate was vacuumed at the vacuum 
pump briefly. At the same time, Lifescreen deluxe beads were centrifuged briefly at 
1500 x g for 15-30 seconds and then mixed with vortex. After that, mix components 
which were given at Table 2.4 were added each wells respectively. 
 
Table 2.6 Identification protocol mix components. 
Component Amount 
Wash Buffer 40 µl 
Serum Sample 12,5 µl 
Class I-II Beads 5 ul 
 
Plate was sealed and incubated for 30 min at room temperature avoiding light in 
shaker. During incubation, conjugant mix was prepared for every sample with 
amount given at Table 2.5 and was stored in the dark until usage.  
Table 2.7 Conjugant mix components. 
Component Amount 
Wash Buffer 45 µl 
Conjugant 5 µl 
 
After incubation of samples, 100 µl wash buffer was added into wells, mixed and 
vacuumed at the vacuum pump briefly. Then, 300 µl wash buffer was added into 
wells, mixed and vacuumed again and this step was repeated three times. 50 µl of 
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prepared conjugant mix were then added into wells. Plate was sealed incubated for 
30 min at room temperature avoiding light in shaker. At the end of the incubation, 
150 µl wash buffer was also added into wells and mixed. Plate was loaded into 
Luminex after necessary wash, calibration was done and all samples were analyzed 
at xMAP software (Luminex Co, Hertogenbosch, The Netherlands). 
2.2.5 Analyze of the samples and statistical analysis 
Analysis of the samples for anti-HLA antibodies screening and identification was 
done with xMAP software analysis tool. Samples with high control values according 
to xMAP software were investigated twice in case eliminating false negative and 
false positive results. Each sample was run twice with positive control serum, 
negative control serum and non-template control (NTC). A typical analysis image 
gained with screenshot in this software was given in Figure 2.1. 
 
Figure 2.1 An image of a typical anti-HLA antibodies screening analysis in xMAP 
software. 
In Figure 2.1, mainly there were two different sections that represent Class I and 
Class II screening results. Each section contains seven different bead results that 
obtain fluorometric measurement from beads. Cl-01 and Cll-01 beads represent IgG 
measurement and other six beads from each section represent IgM results. According 
to adjustment of MFI (mean fluorescence intensity) from each bead, software gave a 
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score changing from 0 to 3. 0 point means negativity and 3 point means positivity. 
Also, 1 and 2 points define low positivity. With those analysis rules, all patients and 
healthy controls were analyzed and their positivity and negativity for anti-HLA 
antibodies were determined. 
An example image of anti-HLA identification analysis is demonstrated in Figure 2.2. 
In the first step of anti-HLA antibodies identification analysis, MFI cutoff value of 
the beads was adjusted into 500-1000 according to adjusted value of beads 
considering raw MFI. Beads which have raw MFI above cutoff value were 
considered as positive, beads under the cutoff value were considered as negative. 
Then, software selected reactive antibodies for each HLA subtype from selective 
epitopes in each positive bead. Thus, reactive antibodies and PRA ratios was 
determined with this analysis.  
 
Figure 2.2 An image of a typical anti-HLA antibodies identification analysis in 
xMAP software. 
Reactive antibodies positive beads above MFI cutoff value were selected according 
to CREGs groups in Table 2.8. Then, class I antibodies were classified for each SLE 
and SSc patients and controls according to CREGs and frequency of CREGs were 
determined. Anti-HLA class-II antibodies were classified without CREGs for all 
groups together as there is no known CREGs classification for Class II antibodies. 
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Table 2.8 CREGs list of reactive antibodies against HLA antigens shared same 
CREG (adapted from Duqesnoy et al., 2003) 
CREG name Reactive antibodies against HLA antigens shared same 
CREG 
INTL3 A11+Cw3+Bw6 
INTL2 A32+A23+A24+A9+Bw4 
5C B51+B52+B35+B53+B62+B63+B71+B72+B75+B76+B77+B5
7+B58+B18 
28C B35+B18+B45+B50+B62+B75+B76+B71+B72+B46+B41+B6
0+B61+B7+B42+B54+B55+B56+B67+B39+B8+B64+B65 
2C1 A2+A28+A68+A69 
B4 B51+B52+B53+B44+B49+B57+B58+B63+B77+B37+B13+B4
7+B27+B38+B59 
22C B7+B22+B54+B55+B56+B27+B17+B57+B58+B46 
2C2 A2+A28+A68+A69+A9+A23+A24 
12C B44+B45+B49+B50+B13+B41+B47+B60+B37+B61 
8C B8+B14+B64+B65+B18+B51+B38+B39 
21C B49+B50+B51+B52+B35+B62+B63+B75+B76+B77 
1C2 A1+A36+A9+A23+A24+A11 
27C B7+B27+B13+B40+B60+B61+B47 
1C3 A25+A26+A34+A66+A11+A1+A36+A29 
1C1 A1+A36+A3+A11 
B6 B35+B18+B45+B50+B62+B75+B76+B71+B72+B46+B41+B6
0+B61+B7+B42+B54+B55+B56+B67+B39+B8+B64+B65 
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For statistical analysis, categorical data was evaluated with chi-square test, and when 
needed Fisher’s exact test was used. The distribution of continuous data was normal, 
so, unpaired t-test was used for comparison. Coefficient Interval (CI) was 95% and 
p<.05 value was accepted as significant unless otherwise stated. 
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3. RESULTS 
3.1 Demographic Data of Patients and Controls 
All demographic data of patients and control were kindly provided from hospital 
files of Trakya University by Rheumatology Department with permission. Four 
different categories that all patients were evaluated as a demographic data such as, 
age, previous pregnancy, history of abortion were indicated. Demographic data of 
SLE and SSc patients and healthy control were given separately for different 
categories in Table 3.1 and also graphics were given in Figure 3.1. 
Table 3.1 Demographic data of SLE, SSc and healthy controls. 
 SLE SSc Controls 
Number (F/M) 77 (73/4) 46 (44/2) 53 
Age (mean) 39.8 48,1 43,2 
Previous Pregnancy n, 
(%) 
66 (85,7) 35 (76,1) 38 (71,7) 
History of abortion n, 
(%) 
6 (7,8) 5 (10,9) 1 (1,9) 
F, Female; M, Male; SLE, systemic lupus erythematosus patient; SSc, Systemic 
sclerosis (scleroderma) patients; %, ratio of patient into selected groups.  
 
a. 
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Figure 3.1. Demographic data of the SLE, SSc patients and healthy controls. All 
demographic data of patients and control were kindly provided from hospital files of 
Trakya University by Rheumatology Department with their permission. 
Demographic data was collected from informed consent form of the subjects. Bar 
graphs of data were drawn with GraphPad Prizm software. a. number of patients who 
had previous pregnancies and history of abortion of were used for systemic lupus 
erythematosus patient (black bar),systemic sclerosis (scleroderma) patients (light 
grey bar) and healthy control group(dark grey). b. age mean with error values for 
systemic lupus erythematosus patient (black bar),systemic sclerosis (scleroderma) 
patients (light grey bar) and healthy control group(dark grey) was used.SLE, 
systemic lupus erythematosus patient; SSc, Systemic sclerosis (scleroderma) 
patients; controls, healthy control group. 
 
According to both Table 3.1 and Figure 3.1, number of female SLE and SSc patients 
was higher than number male patients. Also, number of SLE and SSc patients who 
had an abortion history was also slightly higher than control patient with no abortion 
history. Pregnancy rate was slightly elevated on SLE group rather than SSc and 
control group. 
3.2 Clinical Data of Patients and Controls 
Clinical features of SLE and SSc patients kindly requested from hospital files of 
Trakya University by Rheumatology Department. Involved organs, administered 
therapies and laboratory findings were recorded. Complete physical examination was 
done toall patients by Rheumatology Department. Laboratory data such as whole 
blood counts, biochemical tests, antinuclear antibody (ANA),anti-double-stranded 
DNA (anti-dsDNA) and extractable nuclear antigen (ENA) and those entire tests 
b. 
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were done by Trakya University Central Laboratory. Clinical data of SLE and SSc 
patients and healthy control were given separately for different categories in Table 
3.2.  
Table 3.2 Clinical data of SLE and SSc patients and healthy control that were 
recorded from hospital files. 
 SLE SSc Controls 
Photosensitivity, n (%) 46 (59.7) - 53 
Pleuritis, n (%) 16 (20.8) 1 (2.2) - 
Pericarditis, n (%) 10 (13) 4 (8.7) - 
Nephritis, n (%) 27 (35.1) 1 (2.2) - 
Arthritis, n (%) 59 (76.6) 17 (37) - 
CNS involvement, n (%) 15 (19.5) - - 
Pulmonary hypertension, n 
(%) 
1 (1.3) 16 (34.8) - 
Pulmonary fibrosis, n (%) 1 (1.3) 13 (28.3) - 
Thrombocytopenia, n (%) 10 (13) 1 (2.2) - 
Hemolytic anemia, n (%) 5 (6.5) - - 
Antinuclear antibody, n (%) 76 (98.7) 42 (91.3) - 
Anti-dsDNA, n (%) 38 (49.4) 1 (2.2) - 
Anti-Ro, n (%) 32 (41.6) 5 (10.9) 1 (1.9) 
Anti-RNP, n (%) 23 (29.9) 6 (46) - 
Anti-Sm, n (%) 19 (24.7) - - 
Anti-Ribosomal P, n (%) 7 (9.1) - - 
Anti-centromere, n (%) 1 (1.3) 20 (43.5) - 
Anti-Scl-70, n (%) 0 14 (30.4) - 
APS, n (%) 11 (14.3) 2 (4.4) - 
Digital ulcers, n (%) 0 18 (39.1) - 
Active SLE (SLEDAI >6) 34 (44.2) - - 
Cyclophosphamide usage, n 
(%) 
21 (27.3) 4 (8.7) - 
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n, number of the patient; SLE, systemic lupus erythematosus patient; SSc, Systemic 
sclerosis (scleroderma) patients; %, ratio of patient into selected groups; CNS, 
central nervous system; anti-dsDNA, anti-double-stranded DNA antibodies; anti-
RNP, anti-ribonucleoprotein antibodies; APS, antiphospholipid syndrome; anti-Sm, 
anti-Smith antibodies; SLEDAI, SLE Disease Activity Index. 
As it is represented in Table 3.2, classic parameters of both SLE and SSc showed 
their characteristic frequency specific for each disease. Most of parameters were not 
investigated for healthy controls. Typical parameters for SLE patients such as 
photosensitivity, thrombocytopenia, anti-RNP positivity, anti-Ro positivity, Anti-
nuclear antibody (ANA) etc. had slightly higher frequency than SSc patients. On the 
other hand, SSc parameters frequency such as digital ulcers, anti-centromere, 
pulmonary hypertension, and pulmonary fibrosis were higher in SSc patients. 
3.3 Anti-HLA antibody screening 
For understanding the role of anti-HLA antibodies in SLE and SSc pathogenesis, 
anti-HLA antibodies presence analysis was done. Anti-HLA antibody screening was 
maintained with panel reactive antibody testing that was based on bead specific 
florescence measurement technique. All SLE and SSc patients and healthy controls 
serum was measured with xMAP technology in Luminex device. After analysis with 
xMAP software, software gave a score changing from 0 to 3. 0 point means 
negativity and 3 point means positivity with adjustment of MFI (mean fluorescence 
intensity) from each bead. Also, 1 and 2 points define low positivity. With those 
analysis rules, all patients and healthy controls were analyzed and their positivity and 
negativity for anti-HLA antibodies were determined. With integration of those data, 
anti-HLA antibody positivity of SLE, SSc patients and controls were determined. 
Low and high positivity was considered as a positivity concept which had 3, 2, 1 
points in any bead; negativity was determined 0 points for all seven beads. The 
frequencies of anti-HLA antibodies positivity for SLE, SSc patients and healthy 
controls were given in Table 3.3. Also, frequencies of class I and II anti-HLA 
antibodies positivity for each group were given separately in Table 3.4. Also, 
graphics based on data in Table 3.3 and Table 3.4, percentage of patients and 
controls according to total number in anti-HLA antibodies positivity were given in 
Figure 3.2. 
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Table 3.3 Frequencies of anti-HLA antibodies positivity for SLE, SSc patients and 
healthy controls. 
 SLE SSc Controls 
Anti-HLA 
antibody, n (%) 
38 (49.3) 24 (52.1) 4 (7.5) 
n, number of the patient; SLE, systemic lupus erythematosus patient; SSc, Systemic 
sclerosis (scleroderma) patients; %, ratio of patient into selected groups 
 
Table 3.4 Frequencies of class I and II anti-HLA antibodies positivity for SLE, SSc 
patients and healthy controls. 
 SLE SSc Controls 
Anti-HLA class I 
Antibody, n (%) 
  21 (27.3) 12 (26.1) 1 (1.9) 
Anti-HLA class II 
Antibody, n (%) 
32 (41,6) 19 (41,3) 3 (5,7) 
n, number of the patient; SLE, systemic lupus erythematosus patient; SSc, Systemic 
sclerosis (scleroderma) patients; %, ratio of patient into selected groups 
 
 
a. 
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Figure 3.2. Frequency of anti-HLA antibody positivity in SLE and SSc patient are 
higher than healthy controls. Serum of individuals from SLE, SSc patients and 
healthy controls were studied with panel reactive antibody testing that was based on 
bead specific florescence measurement technique. After analysis in xMAP software, 
number of anti-HLA antibody positive patients and healthy controls were determined 
and percentage of positive patients for each group was evaluated. Bar graphs of data 
were drawn with GraphPad Prizm software. a. percentage of anti-HLA antibody 
positive patients for three different groups. b. percentage of anti-HLA antibody 
positive patients for both Class I and Class II were showed separately (all P<0.001). 
 
As in Table 3.3 and Figure 3.2, SLE and SSc patients had significantly increased  
considering anti-HLA antibody both class I and class II comparison to healthy 
control groups (all P<0.001). When SLE and SSc patients were compared to each 
other, there was no significant difference. Analysis with xMAP software gave a score 
changing from 0 to 3. 0 point means negativity and 3 point means high positivity 
with adjustment of MFI (mean fluorescence intensity) from each bead. Also, 1 and 2 
points define low positivity. According to this analysis, graphic based on number of 
patients and controls in low or high positivity of anti-HLA antibodies were given in 
Figure 3.3. 
 
b. 
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Figure 3.3. Among SLE and SSc patients, high positivity of anti-HLA antibodies are 
higher than low positivity. After working with serum of individuals, analysis was 
done with xMAP software according to manufacturer’s instructions. xMAP software 
gave a score changing from 0 to 3. 0 point means negativity and 3 point means high 
positivity with adjustment of MFI (mean fluorescence intensity) from each bead. 
Also, 1 and 2 points define low positivity. Bar graphs of data were drawn with 
GraphPad Prizm software. SLE patients (black bar), SSc patients (grey bar) and 
healthy controls (white bar) 
As it was shown in Figure 3.3, patients with high positivity for anti-HLA antibodies 
in both SLE and SSc group was found higher than low positivity individuals in same 
groups. However, in healthy controls there was no significant difference between low 
and high positivity for anti-HLA positivity because of lacking sufficient sample size. 
3.4. Anti-HLA antibody identification  
For the further analysis of anti-HLA antibodies in pathogenesis of SLE and SSc 
diseases, anti-HLA antibody identification experiment was done with patients who 
have positive anti-HLA antibody screening. For this reason, 17 SSc patients (6 of 
them both Class I and II positive, 4 of them Class-I positive, 7 of them Class-II 
positive), 37 SLE patients (16 of them both Class I and II positive, 4 of them Class-I 
positive, 13 of them Class-II positive), 4 healthy control (1 of them Class-I positive, 
3 of them Class-II positive) were added to this experiment. In SLE patient group, 21 
of 21 patients who were tested for class-I anti-HLA antibody positivity in 
identification experiment were found positive; 20 patients were found positive for 
class-II anti-HLA antibody and 12 patients were negative. In SSc group, all of 10 
patient who were tested for class-I anti-HLA antibody positivity in identification 
experiment were found positive; 12 patients in total of 13 patients were found 
positive for class-II anti-HLA antibody and 1 patient was negative. In Table 3.5, 
arithmetic mean of PRA ratio for SLE and SSc patient groups in anti-HLA antibody 
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identification experiment were given. Also, column chart for arithmetic mean of 
PRA ratio for SLE and SSc patient groups in anti-HLA antibody was demonstrated 
in Figure 3.4. Healthy control group PRA ratio data was not given due to data 
insufficiency.  
Table 3.5 Arithmetic mean of PRA ratio for SLE and SSc patient groups in anti-
HLA antibody identification experiment 
 
 SLE SSc 
Anti-HLA class I 
Antibody PRA ratio (%) 
41.8 27.4 
Anti-HLA class II 
Antibody PRA ratio (%) 
45.8 40.3 
SLE, systemic lupus erythematosus patient; SSc, Systemic sclerosis (scleroderma) 
patients; %, PRA ratio 
 
Figure 3.4 PRA ratio of SLE patient group is higher than SSc patient group in Class-
I anti-HLA antibody. Serum of individuals from anti-HLA antibody positive SLE, 
SSc patients and healthy controls were studied with anti-HLA antibody identification 
testing that was based on bead specific florescence measurement technique. In the 
first step of anti-HLA antibodies identification analysis, MFI cutoff value of the 
beads was adjusted into 500-1000 according to adjusted value of beads considering 
raw MFI. Beads which have raw MFI above cutoff value were considered as 
positive, beads under the cutoff value were considered as negative. Then, arithmetic 
mean value of PRA ratios belongs each specific group were determined. Bar graphs 
of data were drawn with GraphPad Prizm software. 
As seen in Table 3.5 and Figure 3.4, anti-HLA class I antibody PRA ratio in SLE 
group was slightly increased according to SSc group. In addition, there was no 
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significant difference in anti-HLA class II antibody PRA ratio between SLE and SSc 
patient groups. 
Besides PRA ratio analysis, CREG classification analysis was done in anti-HLA 
antibody identification study. For this step, reactive antibodies against HLA antigens 
in every positive SLE, SSc patients and healthy controls were classified according to 
their CREGs group as in Table 2.8. Totally, frequencies of all CREGs for all PRA 
positive SLE, SSc patients and healthy controls were demonstrated as a column chart 
in Figure 3.5. As seen in Figure 3.5, most common CREGs for class I anti-HLA 
antibodies against class I HLA antigens were B6 and B4. 
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Figure 3.5 Among CREG types, B6 and B4 have higher frequency in total anti-HLA 
antibody positive SLE, SSc patient and healthy controls. Reactive antibodies positive 
beads above MFI cutoff value were selected according to CREGs groups in Table 
2.8. Then, class I antibodies were classified for each SLE and SSc patients and 
controls according to CREGs and frequency of CREGs were determined. Anti-HLA 
class-II antibodies were classified without CREGs for all groups together as there is 
no known CREGs classification for Class II antibodies. Bar graphs of data were 
drawn with GraphPad Prizm software. 
For analysis of anti-HLA class-II antibody identification study, most common 
antibodies against HLA class-II antigens were determined. Accordingly, most 
common anti-HLA class-II antibodies were DQ7, DQ8, DQ9, DQ2; respectively. 
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4. DISCUSSION & CONCLUSION 
In this study, the relationship between anti-HLA antibodies and autoimmunity were 
generally investigated. SLE and SSc were selected as a model autoimmune disorders 
and anti-HLA antibodies presence was compared among SLE, SSc patients and 
healthy controls. We evaluated that the frequencies of both class I and II anti-HLA 
antibodies were increased in both diseases when compared to controls. Also, anti-
HLA antibodies frequencies were similar in SLE and SSc patients. Our findings may 
help to establish the relationship between autoimmune pathogenesis and the anti-
HLA antibodies. 
Generally, anti-HLA antibodies can cause acute and chronic rejection in solid 
transplantation so early allograft rejection happens (Zeevi et al, 2006). According to 
new approach, it has been indicated that there may be a similarity between 
alloimmune responses occur during transplantation and autoimmunity for self-
antigen (Meng et al., 2009; Fukami et al., 2009). Microchimerism is a well-known 
phenomenon effecting after solid transplantation, pregnancy and blood transfusion. 
The analogy between autoimmune diseases and alloimmune response in 
transplantation may explain role of microchimerism related with fetal or maternal 
origin (Nelson et al., 1998; Mosca et al., 2003). It was also indicated that females can 
have autoimmune diseases as a result of an immune reaction between fetal and 
maternal cells (Kekow et al., 2013). Our findings with demographic and clinical data 
of individuals also support this finding with correlation between previous pregnancy 
and anti-HLA antibody positivity (Table 3.1, Figure 3.2).  As in our findings, the 
increased frequency of anti-HLA antibodies in autoimmune diseases like SLE and 
SSc can support the role of microchimerism. 
Anti-class I antibodies can induce the upregulation of inflammatory chemokines, 
growth factors and cytokines so inflammatory cells can accumulate in organs (Nath 
et al., 2010). This accumulation can lead tissue damage and this induction may be the 
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key of similarity between alloimmune responses occur during transplantation and 
autoimmunity for self-antigen. According to our findings, anti-HLA class I 
antibodies had higher frequency in both SLE and SSc patients compared to healthy 
controls (Figure 3.2). Also there have been some studies establishing relationship 
between anti-HLA antibodies and autoimmunity. In their study, Fukami and co-
workers indicated that anti-HLA antibodies against donor antigens in transplantation 
also trigger autoimmune response (2009). Also, Yamagiwa and co-workers in their 
study found in autoimmune hepatitis patients that the frequency of anti-HLA 
antibody increased in autoimmune hepatitis patients compared to patients with non-
autoimmune liver disease and healthy controls (2014).  
In addition, there are several evidences that emphasize the relationship HLA and 
autoimmunity. The studies focus on interaction between some HLA allele subtypes 
with anti-HLA antibodies and autoimmunity. Especially, individuals with HLA-DR 
and HLA-DQ subtypes have increased risk of predisposition to autoimmune diseases 
(Zanelli et al., 2000; Yamagiwa et al., 2014) These studies correlates with our 
findings that most common reactive antibodies in Class-II are DQ epitopes.  
In conclusion, anti-HLA class I and II antibodies were determined as a significantly 
increased in patients of SLE and SSc that were selected as model autoimmune 
diseases compared to healthy controls in which microchimerism is presumed to play 
a role. In order to focus the role of microchimerism in this relationship, more 
targeted studies should be done. 
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